Kenichi Yoshida
YOU?
Author Swipe
View article: Secondary Lower‐Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population‐Based Study
Secondary Lower‐Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population‐Based Study Open
Secondary sarcomas in cervical cancer survivors are understudied. We investigated the incidence and subtypes of secondary sarcomas by treatment modalities, the prognosis of secondary sarcomas, and whether surgery plus radiotherapy increase…
View article: PTHP-06. Molecular Mechanisms and Developmental Pathways of CNS Germ Cell Tumors Elucidated through Whole Genome Analysis
PTHP-06. Molecular Mechanisms and Developmental Pathways of CNS Germ Cell Tumors Elucidated through Whole Genome Analysis Open
BACKGROUND Genomic alterations in germ cell tumors (GCTs) have been identified in the RTK, MAPK, and PI3K pathways through whole exome sequencing, with a prevalence of 71% in germinomas but only 33% in non-germinomas GCTs (NGGCTs). Despite…
View article: Age-specific mutation profiles and their prognostic implications in pediatric <i>KMT2A</i>-rearranged acute myeloid leukemia
Age-specific mutation profiles and their prognostic implications in pediatric <i>KMT2A</i>-rearranged acute myeloid leukemia Open
Driver mutations in KMT2A-rearranged (KMT2A-r) have been identified in acute myeloid leukemia (AML); however, age-related differences in their frequency and prognostic factors remain unclear. In this study, we report age-specific mutation …
View article: PRDM16::SKI is a predictor of aberrant expression of the short variant of PRDM16 in pediatric acute myeloid leukemia
PRDM16::SKI is a predictor of aberrant expression of the short variant of PRDM16 in pediatric acute myeloid leukemia Open
The RNA-sequencing data from the Japanese Children’s Cancer Group (JCCG)’s AML-05 study was re-analyzed to clarify the mechanisms related to high PRDM16 expressions, which is independently associated with adverse outcomes. Results showed t…
View article: 10136- GEN-7 ADDED CLINICAL VALUE OF WHOLE GENOME SEQUENCING FOR PEDIATRIC GLIOMA AND GLIONEURONAL TUMOR
10136- GEN-7 ADDED CLINICAL VALUE OF WHOLE GENOME SEQUENCING FOR PEDIATRIC GLIOMA AND GLIONEURONAL TUMOR Open
BACKGROUND The fifth edition of the WHO Classification of Tumors of the Central Nervous System incorporates numerous genetic findings in pediatric brain tumor classification, emphasizing the significance of molecular diagnostics. In Japan,…
View article: Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients Open
View article: Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma Open
View article: P527: DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA
P527: DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA Open
Background:KMT2A (MLL) rearrangements are among the most frequently occurring chromosomal aberrations in acute myeloid leukemia (AML). The driver mutations in KMT2A-rearranged AML have been identified. Our group showed that KRAS mutations …
View article: Evolutionary histories of breast cancer and related clones
Evolutionary histories of breast cancer and related clones Open
View article: Supplementary Figure from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Figure from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia Open
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
View article: Supplementary Table from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Table from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia Open
Supplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
View article: Data from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
Data from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia Open
Acute erythroid leukemia (AEL) is a unique subtype of acute myeloid leukemia characterized by prominent erythroid proliferation whose molecular basis is poorly understood. To elucidate the underlying mechanism of erythroid proliferation, w…
View article: Supplementary Table from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Table from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia Open
Supplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
View article: Supplementary Figure from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Figure from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia Open
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
View article: Data from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
Data from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia Open
Acute erythroid leukemia (AEL) is a unique subtype of acute myeloid leukemia characterized by prominent erythroid proliferation whose molecular basis is poorly understood. To elucidate the underlying mechanism of erythroid proliferation, w…
View article: Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 126KB, Analyses of two patients with detectable SF3B1 mutations in CD19+, CD34+ and CD14+ fractions.
View article: Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 116KB, Association between acquired mutations (P values of Fisher's exact test for independence) among the 168 patients cohort.
View article: Supplementary Figure S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 170KB, Early mutations affect genes mutated in various human cancers (addition to the main text).
View article: Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
Appropriate cancer care requires a thorough understanding of the natural history of the disease, including the cell of origin, the pattern of clonal evolution, and the functional consequences of the mutations. Using deep sequencing of flow…
View article: Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 336KB, Biological and clinical features of the 24 patients included in the whole-exome study.
View article: Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 336KB, Biological and clinical features of the 24 patients included in the whole-exome study.
View article: Supplementary Table S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 211KB, Biological and clinical features of the 24 patients included in the whole-exome study.
View article: Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 75KB, Details of signature and expression analyses.
View article: Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
Appropriate cancer care requires a thorough understanding of the natural history of the disease, including the cell of origin, the pattern of clonal evolution, and the functional consequences of the mutations. Using deep sequencing of flow…
View article: Supplementary Table S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 98KB, Biological and clinical features of the 168 CLL patients according to EGR2, NFKBIE and BRAF mutations.
View article: Supplementary Figure S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 136KB, Representative flow chart of the sorting procedure.
View article: Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 126KB, Analyses of two patients with detectable SF3B1 mutations in CD19+, CD34+ and CD14+ fractions.
View article: Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 116KB, Association between acquired mutations (P values of Fisher's exact test for independence) among the 168 patients cohort.
View article: Supplementary Figure S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 170KB, Early mutations affect genes mutated in various human cancers (addition to the main text).
View article: Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 75KB, Details of signature and expression analyses.